Valence ロゴ
人気
ログイン

ウォッチリストに追加

Alto Neuroscience Inc.

NYSE: ANRO · リアルタイム株価 · USD
34.28
+0.03 (0.09%)
終値時点： Aug 21, 2026, 3:59 PM
34.28
+0.00%
時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Alto Neuroscience Inc.（ANRO）の株価・分析・データ

0.09%
買気配31.3
時価総額1.35B
売上高（TTM）n/a
純利益（TTM）-84.24M
1.09
-2.32
n/a
-10.43
PBR（TTM）5.49
PSR（TTM）n/a
決算発表日Nov 11, 2026
売気配35.75
出来高238,705
平均出来高（20日）525,098
始値34.44
前日終値34.25
当日レンジ33.66 - 35.29
52週レンジ3.41 - 35.41
アナリストStrong Buy
目標株価37 (7.93%)
配当n/a
権利落ち日n/a

ANROについて

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Feb 2, 2024
従業員数 68
上場取引所 NYSE
ティッカー ANRO
ウェブサイト https://www.altoneuroscience.com
企業情報の全文

業績

2025年のAlto Neuroscienceの売上高は0で、前年の0からundefined%の増加でした。 利益は-63.24Mで、2.94%の増加でした。

財務諸表

アナリスト予想

10件のアナリスト評価によると、ANRO株の平均レーティングは「Strong Buy」です。12か月後の目標株価は37で、直近株価から7.93%の上昇余地となります。

株価予想

決算サプライズ

Alto NeuroscienceはAug 12, 2026に四半期決算を発表しました：
  • 売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
  • EPSは -0.65 で、予想を上回りました 0.12, うち 0.00% の前年比増加にあたります.

次回決算発表

Alto Neuroscience Inc.の決算発表予定日は Nov 11, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード
news image

5日前 · Simply Wall St.

Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?

Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...

news image

6日前 · Simply Wall St.

Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?

Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...

news image

6日前 · Simply Wall St.

Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans

Alto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...

news image

1か月前 · Insider Monkey

Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list. On June 15, ALTO high...

news image

2か月前 · Motley Fool

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office m...

2ページ中1ページ